Dimensional Fund Advisors LP Has $39,000 Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX)

Dimensional Fund Advisors LP lessened its holdings in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) by 17.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 17,544 shares of the company’s stock after selling 3,633 shares during the period. Dimensional Fund Advisors LP owned approximately 0.05% of Anixa Biosciences worth $39,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nations Financial Group Inc. IA ADV lifted its position in shares of Anixa Biosciences by 50.0% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock worth $50,000 after purchasing an additional 7,500 shares during the last quarter. Virtu Financial LLC lifted its position in shares of Anixa Biosciences by 47.2% during the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after purchasing an additional 5,183 shares during the last quarter. Finally, Staley Capital Advisers Inc. acquired a new position in shares of Anixa Biosciences during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. acquired 21,646 shares of Anixa Biosciences stock in a transaction on Tuesday, July 30th. The shares were purchased at an average cost of $3.06 per share, with a total value of $66,236.76. Following the completion of the purchase, the director now owns 890,754 shares in the company, valued at $2,725,707.24. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.60% of the stock is currently owned by corporate insiders.

Anixa Biosciences Price Performance

ANIX stock opened at $3.03 on Wednesday. The business has a fifty day moving average price of $3.21 and a 200 day moving average price of $2.96. Anixa Biosciences, Inc. has a fifty-two week low of $2.14 and a fifty-two week high of $5.13. The stock has a market capitalization of $96.98 million, a price-to-earnings ratio of -8.19 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, equities analysts expect that Anixa Biosciences, Inc. will post -0.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, September 17th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.